Abbvie Inc.

Philip Cox

Michael Z Hoemann

Noel S Wilson

Clara I Villamil

Anil Vasudevan

Kristine E Frank

David J Calderwood

Michael M Friedman

Kelly Mullen

Augustine Osuma

Kevin Patrick Cusack

Xiangdong Xu

Bruce Clapham

Gagandeep K Somal

J Martin Herold

Raymond Huntley

Bin Li

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. 

Heterocyclic kinase inhibitors

The present invention is directed to novel compounds of Formula (I) pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

[object Object]

Growing community of inventors

Grayslake, IL, United States of America

Philip Cox